Regeneron Pharmaceuticals, Inc. ranks in an above-average position in its peer group, with valuation as the main structural strength, while growth is less supportive than the other dimensions. Trend conditions have deteriorated, without yet reaching an extreme downside state. Price behavior is partially reflecting the structural picture, with a moderate gap remaining.
Peer-relative scores, weakest to strongest
Regeneron Pharmaceuticals develops and commercializes biopharmaceutical products, focusing on immunology and oncology. The company follows a pipeline-driven approach in the biotech sector.
The market prices Regeneron based on declining peer quality and operational uncertainty, not on sustained growth strength. With gross margin at 77%, down from 81% year-on-year, and operating margin at 29.5%, the company faces biosimilar competition and operational setbacks such as the fianlimab trial. These setbacks prompt the market to discount Regeneron more aggressively, as each operational stumble is reflected in lower confidence in stable returns. Within biotech, the market penalizes Regeneron more harshly for pipeline setbacks and biosimilar pressure than it does for peers with more stable revenue bases, making its margin volatility a greater concern for investors. As a result, the stock trades at a discount below peer levels, reflecting compensation for these operational risks. Only a sustained margin recovery and clear pipeline execution can break the peer-discount framing.
Break down REGN's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.